Gene-Environment Interaction in Parkinson's Disease: Coffee, ADORA2A, and CYP1A2

Neuroepidemiology

Volumn 47, Issue 3-4, 2017, Pages 192-200

  Chuang, Yu Hsuan ^a   Lill, Christina M ^c   Lee, Pei Chen ^d   Hansen, Johnni ^e   Lassen, Christina F ^e   Bertram, Lars ^c,f   Greene, Naomi ^a   Sinsheimer, Janet S ^a,b   Ritz, Beate ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF LÜBECK   (Germany)

^d NATIONAL TAIPEI UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Taiwan)

^e DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Adenosine A2A receptor (ADORA2A); Caffeine; Cytochrome P450 1A2 (CYP1A2); Meta analysis; Parkinson's disease

Indexed keywords

CYTOCHROME P450 1A2; ADENOSINE A2A RECEPTOR; CYP1A2 PROTEIN, HUMAN;

ADORA2A GENE; ADULT; ARTICLE; CASE CONTROL STUDY; COFFEE; CONTROLLED STUDY; CYP1A2 GENE; DENMARK; DISEASE ASSOCIATION; FEMALE; FOOD INTAKE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; RISK FACTOR; AGED; GENETICS; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; COFFEE; CYTOCHROME P-450 CYP1A2; DENMARK; FEMALE; GENE-ENVIRONMENT INTERACTION; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, ADENOSINE A2A; RISK FACTORS;

EID: 85015768132     PISSN: 02515350     EISSN: 14230208     Source Type: Journal    
DOI: 10.1159/000450855     Document Type: Article

References (27)

1. Nefzger MD, Quadfasel FA, Karl VC: A retrospective study of smoking in Parkinson's disease. Am J Epidemiol 1968; 88: 149-158.
2. Hellenbrand W, Seidler A, Boeing H, Robra BP, Vieregge P, Nischan P, Joerg J, Oertel WH, Schneider E, Ulm G: Diet and Parkinson's disease. I: a possible role for the past intake of specific foods and food groups. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology 1996; 47: 636-643.
3. Hernán MA, Takkouche B, Caamaño-Isorna F, Gestal-Otero JJ: A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002; 52: 276-284.
4. Kenborg L, Lassen CF, Ritz B, Andersen KK, Christensen J, Schernhammer ES, Hansen J, Wermuth L, Rod NH, Olsen JH: Lifestyle, family history, and risk of idiopathic Parkinson disease: a large Danish case-control study. Am J Epidemiol 2015; 181: 808-816.
5. Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, Tanner CM, Masaki KH, Blanchette PL, Curb JD, Popper JS, White LR: Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000; 283: 2674-2679.
6. Saaksjarvi K, Knekt P, Rissanen H, Laaksonen MA, Reunanen A, Mannisto S: Prospective study of coffee consumption and risk of Parkinson's disease. Eur J Clin Nutr 2008; 62: 908-915.
7. Qi H, Li S: Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson's disease. Geriatr Gerontol Int 2014; 14: 430-439.
8. Xu K, Xu YH, Chen JF, Schwarzschild MA: Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease. Neuroscience 2010; 167: 475-481.
9. Popat RA, Van Den Eeden SK, Tanner CM, Kamel F, Umbach DM, Marder K, Mayeux R, Ritz B, Ross GW, Petrovitch H, Topol B, McGuire V, Costello S, Manthripragada AD, Southwick A, Myers RM, Nelson LM: Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease. Eur J Neurol 2011; 18: 756-765.
10. Facheris MF, Schneider NK, Lesnick TG, de Andrade M, Cunningham JM, Rocca WA, Maraganore DM: Coffee, caffeine-related genes, and Parkinson's disease: a case-control study. Mov Disord 2008; 23: 2033-2040.
11. Tan EK, Lu ZY, Fook-Chong SM, Tan E, Shen H, Chua E, Yih Y, Teo YY, Zhao Y: Exploring an interaction of adenosine A2A receptor variability with coffee and tea intake in Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 2006; 141B:634-636.
12. Hill-Burns EM, Hamza TH, Zabetian CP, Factor SA, Payami H: An attempt to replicate interaction between coffee and CYP1A2 gene in connection to Parkinson's disease. Eur J Neurol 2011; 18:e107-e108; author reply e109.
13. Gebhardt SE, Thomas RG: Nitritive Value of Foods. Beltsville, US Department of Agriculture, Agricultural Research Service, Nutrient Data Laboratory, 2000, p 11.
14. Hamza TH, Chen H, Hill-Burns EM, Rhodes SL, Montimurro J, Kay DM, Tenesa A, Kusel VI, Sheehan P, Eaaswarkhanth M, Yearout D, Samii A, Roberts JW, Agarwal P, Bordelon Y, Park Y, Wang L, Gao J, Vance JM, Kendler KS, Bacanu SA, Scott WK, Ritz B, Nutt J, Factor SA, Zabetian CP, Payami H: Genomewide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee. PLoS Genet 2011; 7:e1002237.
15. Ahmed I, Lee PC, Lill CM, Searles Nielsen S, Artaud F, Gallagher LG, Loriot MA, Mulot C, Nacfer M, Liu T, Biernacka JM, Armasu S, Anderson K, Farin FM, Lassen CF, Hansen J, Olsen JH, Bertram L, Maraganore DM, Checkoway H, Ritz B, Elbaz A: Lack of replication of the GRIN2A-by-coffee interaction in Parkinson disease. PLoS Genet 2014; 10:e1004788.
16. Danmarks Statistik: Indvandrere i Danmark 2015. 2015. http://www.dst.dk/da/Statistik/Publikationer/VisPub?cid=20703.
17. Friedrich T: Generalised Inference in the Random Effects Meta Regression Model. 2013. http://www2.uaem.mx/r-mirror/web/packages/metagen/metagen.pdf.
18. Byrne EM, Johnson J, McRae AF, Nyholt DR, Medland SE, Gehrman PR, Heath AC, Madden PA, Montgomery GW, Chenevix-Trench G, Martin NG: A genome-wide association study of caffeine-related sleep disturbance: confirmation of a role for a common variant in the adenosine receptor. Sleep 2012; 35: 967-975.
19. Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M, Sonsalla PK, Castagnoli K, Castagnoli N Jr, Schwarzschild MA: Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 2001; 21:RC143.
20. Pierri M, Vaudano E, Sager T, Englund U: KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse. Neuropharmacology 2005; 48: 517-524.
21. Alsene K, Deckert J, Sand P, de Wit H: Association between A2A receptor gene polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 2003; 28: 1694-1702.
22. Ferre S, Quiroz C, Woods AS, Cunha R, Popoli P, Ciruela F, Lluis C, Franco R, Azdad K, Schiffmann SN: An update on adenosine A2Adopamine D2 receptor interactions: implications for the function of G protein-coupled receptors. Curr Pharm Des 2008; 14: 1468-1474.
23. Franco R, Ferre S, Agnati L, Torvinen M, Gines S, Hillion J, Casado V, Lledo P, Zoli M, Lluis C, Fuxe K: Evidence for adenosine/dopamine receptor interactions: indications for heteromerization. Neuropsychopharmacology 2000; 23(4 suppl):S50-S59.
24. Gunes A, Dahl ML: Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics 2008; 9: 625-637.
25. Backman JT, Schroder MT, Neuvonen PJ: Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine. Eur J Clin Pharmacol 2008; 64: 17-24.
26. Sachse C, Brockmoller J, Bauer S, Roots I: Functional significance of a C->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999; 47: 445-449.
27. Mellick GD, Ross OA: Caffeine and Parkinson's disease: are we getting our fix on riskmodifying gene-environment interactions? Eur J Neurol 2011; 18: 671-672.